 |
answer text |
<p>UK Research and Innovation is funded by the Department for Business, Energy and
Industrial Strategy and supports basic research into the development of new drugs
including pre-clinical research and early stage clinical trials. It does not routinely
analyse data on the number of trials specifically relating to the development of new
drugs.</p><p> </p><p>UK Research and Innovation supports clinical trials through the
Medical Research Council (MRC) including early phase clinical stage trials through
‘response mode’ schemes such as the Developmental Pathway Funding Scheme, which supports
pre-clinical development and early clinical trial of novel therapeutics including
new and repurposing of existing therapies.</p><p> </p><p>Later stage trials are funded
through the Efficacy and Mechanism Evaluation Programme (which is a jointly funded
partnership between MRC and the National Institute for Health Research). The MRC also
supports:</p><p> </p><ul><li>The Joint Global Health Trials programme in partnership
with the National Institute for Health Research, the Department for International
Development and the Wellcome Trust.</li><li>The European Developing Countries Clinical
Trials programme (EDCTP), with a specific focus on poverty-related infectious diseases
in Sub-Saharan Africa.</li></ul><p> </p><p>These provide funding to later stage trials
including studies evaluating the efficacy and effectiveness of interventions with
potential to make a step-change in the promotion of health, treatment of disease and
improvement of rehabilitation or long-term care.</p><p> </p><p>A recent example of
a clinical trial project for a new medicine is the award of over £2.7 million for
a Clinical Trial of a Novel Treatment for <em>Clostridium difficile (</em>associated
diarrhoea) from Innovate UK as part of the Biomedical Catalyst. This was awarded to
MGB Biopharma Ltd based in Glasgow for this new class of small molecule antibiotic.</p>
|
|
